Insmed (INSM) call put ratio 1 call to 1.8 puts as share price up 116%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- Netflix raises prices in Germany and Austria, Citi comments
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Insmed (INSM) PT Raised to $67 at Stifel
May 30, 2024 4:35 PM EDTStifel analyst Stephen D. Willey raised the price target on Insmed (NASDAQ: INSM) to $67.00 (from $39.00) while maintaining a Buy rating.
The analyst comments "We believe topline P3 ASPEN results will establish brensocatib as the first-approved, standardof-care therapy in NCFBE and meaningfully improve investor... More
Insmed (INSM) PT Raised to $58 at UBS
May 29, 2024 5:37 AM EDTUBS analyst Trung Huynh raised the price target on Insmed (NASDAQ: INSM) to $58.00 (from $46.00) while maintaining a Buy rating.
The analyst comments "Management believes from now through the regulatory review process, the path is noncontroversial given the strength of data presented... More
Insmed (INSM) PT Raised to $68 at Truist Securities
May 29, 2024 5:30 AM EDTTruist Securities analyst Nicole Germino raised the price target on Insmed (NASDAQ: INSM) to $68.00 (from $48.00) while maintaining a Buy rating.
The analyst comments "With greater confidence into brensocatib potential approval following positive ASPEN results today and supported by our KOL call last... More
Insmed (INSM) PT Raised to $54 at Wolfe Research
May 29, 2024 5:25 AM EDTWolfe Research analyst Andy Chen raised the price target on Insmed (NASDAQ: INSM) to $54.00 (from $42.00) while maintaining a Outperform rating.
The analyst comments "How to think about stock valuation, even assuming a capital raise? The previous stock in the mid-$20s implied POS... More
Insmed (INSM) PT Raised to $62 at BofA Securities
May 29, 2024 5:08 AM EDTBofA Securities analyst Jason Zemansky raised the price target on Insmed (NASDAQ: INSM) to $62.00 (from $40.00) while maintaining a Buy rating.
The analyst comments "This mornings positive readout for novel DPP-1 inhibitor brenso (see report: our initial takes on the data) represents a... More
